Premium
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy
Author(s) -
Desta Zeruesenay,
Gammal Roseann S.,
Gong Li,
WhirlCarrillo Michelle,
Gaur Aditya H.,
Sukasem Chonlaphat,
Hockings Jennifer,
Myers Alan,
Swart Marelize,
Tyndale Rachel F.,
Masimirembwa Collen,
Iwuchukwu Otito F.,
Chirwa Sanika,
Lennox Jeffrey,
Gaedigk Andrea,
Klein Teri E.,
Haas David W.
Publication year - 2019
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1477
Subject(s) - efavirenz , cyp2b6 , reverse transcriptase inhibitor , pharmacogenetics , medicine , discontinuation , pharmacology , guideline , adverse effect , genotype , antiretroviral therapy , virology , human immunodeficiency virus (hiv) , cyp1a2 , cytochrome p450 , biology , genetics , viral load , pathology , metabolism , gene
The HIV type‐1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type‐1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.